These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

962 related articles for article (PubMed ID: 26617852)

  • 1. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
    Chen Y; Song J; Jiang Y; Yu C; Ma Z
    Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
    Lin Y; Zhong Y; Guan H; Zhang X; Sun Q
    J Exp Clin Cancer Res; 2012 Jul; 31(1):59. PubMed ID: 22762532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
    Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
    Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
    Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
    Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
    Gudadze M; Kankava Q; Mariamidze A; Burkadze G
    Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
    Mylona E; Giannopoulou I; Fasomytakis E; Nomikos A; Magkou C; Bakarakos P; Nakopoulou L
    Hum Pathol; 2008 Jul; 39(7):1096-102. PubMed ID: 18495204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
    Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
    Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
    Liu C; Luo Y; Liu X; Lu P; Zhao Z
    Cancer Biother Radiopharm; 2012 Jun; 27(5):324-8. PubMed ID: 22702496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.
    Li W; Liu F; Lei T; Xu X; Liu B; Cui L; Wei J; Guo X; Lang R; Fan Y; Gu F; Tang P; Zhang X; Fu L
    Pathol Res Pract; 2010 Dec; 206(12):828-34. PubMed ID: 20977976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.
    Abraham BK; Fritz P; McClellan M; Hauptvogel P; Athelogou M; Brauch H
    Clin Cancer Res; 2005 Feb; 11(3):1154-9. PubMed ID: 15709183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.
    Gudadze M; Kankava K; Mariamidze A; Mosidze T; Burkadze G
    Georgian Med News; 2013 Sep; (222):50-7. PubMed ID: 24099815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients.
    Horiguchi K; Toi M; Horiguchi S; Sugimoto M; Naito Y; Hayashi Y; Ueno T; Ohno S; Funata N; Kuroi K; Tomita M; Eishi Y
    J Med Dent Sci; 2010 Jun; 57(2):165-75. PubMed ID: 21073135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
    Lü X; Xu K; Lü H; Yin Y; Ma C; Liu Y; Li H; Suo Z
    Ultrastruct Pathol; 2011 Apr; 35(2):72-8. PubMed ID: 21299347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The distribution of CD44+/CD24- cancer stem cells in breast cancer and its relationship with prognostic factors.
    Cabuk D; Yetimoglu E; Simsek T; Gacar G; Subasi C; Canturk Z; Ercin C; Karaoz E; Uygun K
    J BUON; 2016; 21(5):1121-1128. PubMed ID: 27837613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hedgehog signaling pathway is associated with poor prognosis in breast cancer patients with the CD44+/CD24‑ phenotype.
    Zhao H; Tang H; Xiao Q; He M; Zhao L; Fu Y; Wu H; Yu Z; Jiang Q; Yan Y; Jin F; Wei M
    Mol Med Rep; 2016 Dec; 14(6):5261-5270. PubMed ID: 27779682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
    Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
    J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.
    Nogi H; Suzuki M; Kamio M; Kato K; Kawase K; Toriumi Y; Takeyama H; Fukushima H; Morikawa T; Uchida K
    Oncol Rep; 2011 Apr; 25(4):1109-15. PubMed ID: 21308353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
    Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
    Kai M; Onishi H; Souzaki M; Tanaka H; Kubo M; Tanaka M; Katano M
    Cancer Sci; 2011 Dec; 102(12):2132-8. PubMed ID: 21838786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.